title: Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer.
abstract: OBJECTIVE
  Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane.
  
  
  METHODS
  We evaluated the use of a GP regimen (1,000 mg/m(2) gemcitabine administered on days 1 and 8 plus 60 mg/m(2) cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.
  
  
  RESULTS
  The median patient age was 49 years (age range, 35 approximately 69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14 approximately 44%). The median time to progression was 5.2 months (95% CI, 3.6 approximately 6.8 months). Median survival was 19.5 months (95% CI, 11.2 approximately 27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade 1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths.
  
  
  CONCLUSIONS
  Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.
authors.affiliation: Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
authors.forename: Jung Hwan
authors.initials: JH
authors.lastname: Kim
authors.forename: Sung Yong
authors.initials: SY
authors.lastname: Oh
authors.forename: Hyuk-Chan
authors.initials: HC
authors.lastname: Kwon
authors.forename: Suee
authors.initials: S
authors.lastname: Lee
authors.forename: Sung-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Dae-Cheol
authors.initials: DC
authors.lastname: Kim
authors.forename: Jin-Hwa
authors.initials: JH
authors.lastname: Lee
authors.forename: Hyung-Sik
authors.initials: HS
authors.lastname: Lee
authors.forename: Se-Heun
authors.initials: SH
authors.lastname: Cho
authors.forename: Hyo-Jin
authors.initials: HJ
authors.lastname: Kim
references.citation: Cancer Chemother Pharmacol. 2006 May;57(5):640-6
references.pmid: 16163537
references.citation: Semin Oncol. 1997 Apr;24(2 Suppl 7):S7-17-S7-23
references.pmid: 9194475
references.citation: Breast. 2000 Dec;9(6):338-42
references.pmid: 14965758
references.citation: Oncology (Williston Park). 2003 Dec;17(12 Suppl 14):26-32
references.pmid: 14768402
references.citation: N Engl J Med. 1998 Oct 1;339(14):974-84
references.pmid: 9753714
references.citation: Ann Oncol. 2001 Sep;12(9):1259-64
references.pmid: 11697837
references.citation: Oncology. 2003;64(3):191-206
references.pmid: 12697958
references.citation: Clin Breast Cancer. 2001 Oct;2(3):190-208; discussion 209
references.pmid: 11899413
references.citation: Oncology. 2001;60(4):303-7
references.pmid: 11408796
references.citation: Cancer Res. 2001 Dec 15;61(24):8723-9
references.pmid: 11751391
references.citation: Semin Oncol. 2006 Jun;33(3 Suppl 9):S19-23
references.pmid: 16797378
references.citation: Semin Oncol. 2003 Apr;30(2 Suppl 3):6-10
references.pmid: 12722018
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Cancer Invest. 2004;22(5):655-62
references.pmid: 15581045
references.citation: J Clin Oncol. 2002 Jan 1;20(1):37-41
references.pmid: 11773151
references.citation: J Clin Oncol. 2000 Jun;18(11):2245-9
references.pmid: 10829044
references.citation: Oncology. 2002;62(1):2-8
references.pmid: 11810037
references.citation: Anticancer Drugs. 1999 Feb;10(2):155-62
references.pmid: 10211545
references.citation: Cancer Invest. 2000;18(6):503-9
references.pmid: 10923097
references.citation: Ann Oncol. 2000 Apr;11(4):495-6
references.pmid: 10847474
references.citation: Semin Oncol. 2006 Feb;33(1 Suppl 2):S6-14
references.pmid: 16472712
references.citation: Ann Oncol. 2004 Jan;15(1):95-9
references.pmid: 14679126
references.citation: Cancer Res Treat. 2004 Apr;36(2):103-14
references.pmid: 20396549
references.citation: Oncology. 2004;66(1):18-23
references.pmid: 15031594
references.citation: Ann Oncol. 2000 Jul;11(7):873-5
references.pmid: 10997817